Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleonora Distrutti

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
Trends in Pharmacological Sciences|April 5, 2002
Role of PAR2 in pain and inflammationStefano Fiorucci, Eleonora Distrutti
Trends in Molecular Medicine|November 24, 2021
Linking liver metabolic and vascular disease via bile acid signalingStefano Fiorucci, Eleonora Distrutti
Handbook of Experimental Pharmacology|June 16, 2019
The Pharmacology of Bile Acids and Their ReceptorsStefano Fiorucci, Eleonora Distrutti
Trends in Molecular Medicine|October 21, 2015
Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic DisordersStefano Fiorucci, Eleonora Distrutti
Handbook of Experimental Pharmacology|July 4, 2019
Chenodeoxycholic Acid: An Update on Its Therapeutic ApplicationsStefano Fiorucci, Eleonora Distrutti
Current Topics in Medicinal Chemistry|February 20, 2007
Cyclo-oxygenase (COX) inhibiting nitric oxide donating (CINODs) drugs: a review of their current statusFiorucci Stefano, Eleonora Distrutti
Pharmacological Research|August 1, 2016
Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertensionStefano Fiorucci, Eleonora Distrutti
Recent Advances in Inflammation & Allergy Drug Discovery|June 2, 2023
Bile Acids and SARS-CoV-2: Ursodeoxycholic Acid as a Potential Treatment of COVID-19Stefano Fiorucci, Ginevra Urbani, Eleonora Distrutti
Digestive Diseases and Sciences|April 4, 2018
Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel DiseasesStefano Fiorucci, Michele Biagioli, Eleonora Distrutti
Current Topics in Medicinal Chemistry|January 17, 2012
Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disordersStefano Fiorucci, Angela Zampella, Eleonora Distrutti
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
Trends in Pharmacological Sciences|April 5, 2002
Role of PAR2 in pain and inflammationStefano Fiorucci, Eleonora Distrutti
Trends in Molecular Medicine|November 24, 2021
Linking liver metabolic and vascular disease via bile acid signalingStefano Fiorucci, Eleonora Distrutti
Handbook of Experimental Pharmacology|June 16, 2019
The Pharmacology of Bile Acids and Their ReceptorsStefano Fiorucci, Eleonora Distrutti
Trends in Molecular Medicine|October 21, 2015
Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic DisordersStefano Fiorucci, Eleonora Distrutti
Handbook of Experimental Pharmacology|July 4, 2019
Chenodeoxycholic Acid: An Update on Its Therapeutic ApplicationsStefano Fiorucci, Eleonora Distrutti
Current Topics in Medicinal Chemistry|February 20, 2007
Cyclo-oxygenase (COX) inhibiting nitric oxide donating (CINODs) drugs: a review of their current statusFiorucci Stefano, Eleonora Distrutti
Pharmacological Research|August 1, 2016
Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertensionStefano Fiorucci, Eleonora Distrutti
Recent Advances in Inflammation & Allergy Drug Discovery|June 2, 2023
Bile Acids and SARS-CoV-2: Ursodeoxycholic Acid as a Potential Treatment of COVID-19Stefano Fiorucci, Ginevra Urbani, Eleonora Distrutti
Digestive Diseases and Sciences|April 4, 2018
Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel DiseasesStefano Fiorucci, Michele Biagioli, Eleonora Distrutti
Current Topics in Medicinal Chemistry|January 17, 2012
Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disordersStefano Fiorucci, Angela Zampella, Eleonora Distrutti
Pageof 15